Promomed: Skivira (a drug for the treatment of COVID-19)

Main article: Drugs from Coronavirus COVID-19

2022: Inclusion in the list of drugs for the treatment of COVID-19

The list of drugs for the treatment of COVID-19 also includes the drug Skivira manufactured by Promomed Group of Companies, which announced this on August 24, 2022.

The current version of the guidelines for the prevention, diagnosis and treatment of coronavirus infection, prepared by Russian experts in the field of infectious diseases, is available on the website of the Ministry of Health of the Russian Federation.

A drug for targeted etiotropic therapy of COVID-19 based on nirmatrelvir and ritonavir, created using a special technology, from the latest generation of drugs. Skyvira attacks completely different targets specific to the coronavirus. In other words, the drug completely blocks the process of reproduction of the virus inside the cell. Ritonavir, acting as a pharmacokinetic enhancer, provides long-term maintenance of the necessary concentration of nirmatrelvir in the body and increases the effectiveness of therapy.

Clinical studies have shown a pronounced antiviral effect of a new drug for the treatment of COVID-19, reducing the risk of disease progression to more severe forms and accelerating recovery. The directed mechanism of action on the viral protease determines the success of treatment regardless of the SARS-CoV-2 strain. As of August 2022, Promomed's Skivir drug can be indicated for outpatient treatment of coronavirus infection of the lung or moderate course in adults, - said Vladimir Chulanov, chief freelance specialist in infectious diseases of the Ministry of Health of the Russian Federation, deputy. Director for Scientific Work and Innovative Development of the Federal State Budgetary Institution "National Medical Research Center for Phthisiopulmo-Nology and Infectious Diseases" of the Ministry of Health of the Russian Federation.

Each drug in Promomed's antiviral portfolio makes it possible to have a more personalized approach to patient therapy, taking into account concomitant pathology, drug interactions, duration of symptom manifestation, etc., and therefore more effective treatment, - commented Kira Zaslavskaya, director of new products at Promomed Group of Companies.

For the treatment of COVID-19 in adults, a daily dose of 600 mg of nirmatrelvir + 200 mg of ritonavir (1 tablet 2 times a day) is indicated with a course of treatment of 5 days. Treatment is recommended to begin as early as possible after the diagnosis of a new coronavirus infection and/or within 5 days after the appearance of the first symptoms of the disease.